

1 Local genetic correlations exist among 2 neurodegenerative and neuropsychiatric 3 diseases

4
5 Regina H. Reynolds^{1,2,#}, Aaron Z. Wagen^{1,3,4,#}, Frida Lona-Durazo⁵, Sonja W. Scholz^{6,7}, Maryam
6 Shoai^{8,10}, John Hardy^{2,8,10}, Sarah A. Gagliano Taliun^{5,9}, Mina Ryten^{1,2,11}

7 # These authors contributed equally to this work.

8 Author affiliations

- 9 1. Genetics and Genomic Medicine, Great Ormond Street Institute of Child Health, University
10 College London, London, UK
- 11 2. Aligning Science Across Parkinson's (ASAP) Collaborative Research Network, Chevy Chase,
12 MD 20815, United States
- 13 3. Department of Clinical and Movement Neurosciences, Queen Square Institute of Neurology,
14 London, UK
- 15 4. Neurodegeneration Biology Laboratory, The Francis Crick Institute, London, UK
- 16 5. Montréal Heart Institute, Montréal, Québec, Canada
- 17 6. Neurodegenerative Diseases Research Unit, National Institute of Neurological Disorders and
18 Stroke, Bethesda, MD, USA
- 19 7. Department of Neurology, Johns Hopkins University Medical Center, Baltimore, MD, USA
- 20 8. Department of Neurodegenerative Diseases, Queen Square Institute of Neurology,
21 University College London, London, UK
- 22 9. Department of Medicine & Department of Neurosciences, Université de Montréal, Montréal,
23 Québec, Canada
- 24 10. UK Dementia Research Institute, University College London, London, UK
- 25 11. NIHR Great Ormond Street Hospital Biomedical Research Centre, University College London,
26 London, UK

27

28 **Correspondence to:** Regina H. Reynolds (regina.reynolds.16@ucl.ac.uk) & Mina Ryten

29 (mina.ryten@ucl.ac.uk)

30 **Abstract**

31 Genetic correlation (r_g) between traits can offer valuable insight into underlying shared biological
32 mechanisms. Neurodegenerative diseases overlap neuropathologically and often manifest comorbid
33 neuropsychiatric symptoms. However, global r_g analyses show minimal r_g among neurodegenerative
34 and neuropsychiatric diseases. Importantly, local r_g s can exist in the absence of global relationships.
35 To investigate this possibility, we applied LAVA, a tool for local r_g analysis, to genome-wide
36 association studies of 3 neurodegenerative diseases (Alzheimer's disease, Lewy body dementia and
37 Parkinson's disease) and 3 neuropsychiatric disorders (bipolar disorder, major depressive disorder
38 and schizophrenia). We identified several local r_g s missed in global analyses, including between (i) all
39 3 neurodegenerative diseases and schizophrenia and (ii) Alzheimer's and Parkinson's disease. For
40 those local r_g s identified in genomic regions containing disease-implicated genes, such as *SNCA*, *CLU*
41 and *APOE*, incorporation of expression quantitative trait loci suggested that genetic overlaps
42 between diseases may be driven by more than one gene. Collectively, we demonstrate that complex
43 genetic relationships exist among neurodegenerative and neuropsychiatric diseases, highlighting
44 putative pleiotropic genomic regions and genes. These findings imply sharing of pathogenic
45 processes and the potential existence of common therapeutic targets.

46 **Abbreviations:** AD = Alzheimer's disease; BIP = bipolar disorder; bp = base pair; CI = confidence
47 interval; DLB = dementia with Lewy bodies; eQTL = expression quantitative loci; FDR = false discovery
48 rate; GWAS = genome-wide association study; kb = kilobase; LAVA = local analysis of [co]variant
49 annotation; LBD = Lewy body dementia; LD = linkage disequilibrium; LDSC = linkage disequilibrium
50 score regression; MDD = major depressive disorder; PD = Parkinson's disease; SCZ = schizophrenia;
51 SNP = single nucleotide polymorphism; UKBB = UK Biobank; ρ = rho; r_g = genetic correlation

52 **Introduction**

53 Neurodegenerative diseases are a group of syndromically-defined disorders that are characterised
54 by the progressive loss of the structure and function of the central nervous system. They are
55 typically grouped by their predominant neuropathological protein deposit (e.g. synucleinopathies by
56 α -synuclein deposition), but more often than not, they present with co-pathologies, suggesting that
57 they might share common pathogenic pathways^{1,2}. This notion is supported by genome-wide
58 association studies (GWASs), which have (i) identified shared risk loci across neurodegenerative
59 diseases, such as *APOE* and *BIN1* in Alzheimer's disease (AD) and Lewy body dementia (LBD), or *GBA*,
60 *SNCA*, *TMEM175* in Parkinson's disease (PD) and LBD and (ii) demonstrated that genetic risk scores
61 derived from one neurodegenerative disease can predict risk of another, as with AD and PD scores
62 predicting risk of LBD³⁻⁵. The importance of identifying common pathogenic processes cannot be
63 overstated, given the implications for our mechanistic understanding of these diseases as well as
64 identification of common therapeutic targets benefitting a wider range of patients.

65 From a clinical perspective, neurodegenerative diseases are often also defined in terms of their
66 predominant symptom (e.g. AD by memory impairment or PD by parkinsonism), but in reality,
67 present as highly heterogenous diseases, with symptoms spanning multiple domains including
68 neuropsychiatric symptoms^{6,7}. Indeed, a higher prevalence of depression has been observed in
69 individuals with dementia compared to those without dementia.⁸ Furthermore, depression and
70 anxiety are more common in individuals with PD compared to the general population, with clinically
71 significant symptoms in 30-35% of patients^{9,10}. A similar (albeit reversed) phenomenon has been
72 observed in some neuropsychiatric disorders, with a higher risk of dementia diagnoses observed in
73 individuals with schizophrenia (SCZ) versus individuals without a history of serious mental illness^{11,12}
74 and a higher risk of PD in individuals diagnosed with depressive disorder in mid or late life^{10,13,14}.
75 Together, these observations suggest the possibility of intersecting pathways between
76 neurodegenerative and neuropsychiatric diseases.

77 Importantly, clinical and neuropathological overlaps are not reflected in global genetic correlations
78 (r_g), with a recent study of global r_g between neurological phenotypes demonstrating limited
79 overlap between individual neurodegenerative diseases as well as between neurodegenerative
80 diseases and neuropsychiatric disorders^{15,16}. One explanation for the lack of global genetic
81 correlation is that global studies only consider the average r_g across the entire genome. A genome-
82 wide average of r_g may fail to detect strong local r_g s confined to specific genomic regions or local r_g s
83 that have opposing directions across the genome^{15,17}. This limitation can be addressed with recently-
84 developed bioinformatics tools such as local analysis of [co]variant annotation (LAVA), which is able
85 to evaluate local heritability over multiple traits of interest (using summary statistics) and detect
86 local regions of shared genetic association¹⁸. Here, we apply LAVA to GWASs derived from 3
87 neurodegenerative diseases (AD, LBD and PD)^{3,5,19,20} and 3 neuropsychiatric disorders (bipolar disorder,
88 BIP; major depressive disorder, MDD; and SCZ)²¹⁻²³. In addition, we use data from blood- and brain-
89 derived gene expression traits, in the form of expression quantitative loci (eQTLs), to facilitate
90 functional interpretation of local r_g s between disease traits.

91 **Results**

92 **Local analyses reveal genetic correlations among neurodegenerative and** 93 **neuropsychiatric diseases**

94 We applied LAVA to 3 neurodegenerative diseases (AD, LBD and PD) and 3 neuropsychiatric
95 disorders (BIP, MDD and SCZ) (**Table 1**), all of which represent globally prevalent diseases²⁴. Among
96 neurodegenerative diseases, AD and PD are the most common, with a global prevalence of 8.98%
97 and 1.12% in individuals > 70 years of age^{6,24,25} and consequently, have large GWAS cohorts (AD, N
98 cases = 71,880; PD, N cases = 33,674)^{3,19}. LBD is the second most common dementia subtype after
99 AD, affecting between 4.2-30% of dementia patients²⁶. As such, the LBD GWAS cohort is small (N
100 cases = 2,591), but unlike AD and PD neurodegenerative GWASs, 69% of the cohort is pathologically
101 defined⁵. Among neuropsychiatric disorders, MDD is the second most prevalent, with an estimated
102 185 million people affected globally (equivalent to 2.49% of the general population), while BIP and
103 SCZ have a prevalence of 0.53% and 0.32%, respectively²⁴. Accordingly, all 3 disorders have large,
104 well-powered GWASs (BIP, N cases = 41,917; MDD, N cases = 170,756; SCZ, N cases = 40,675)²¹⁻²³.
105 We tested pairwise local genetic correlations (r_g s) across a targeted subset of 300 local autosomal
106 genomic regions that contain genome-wide significant GWAS loci from at least one trait
107 (**Supplementary Figure 1, Supplementary Table 1**). These genomic regions, henceforth referred to
108 as linkage disequilibrium (LD) blocks, were filtered from the original 2,495 LD blocks generated by
109 Werme *et al.*¹⁸ using a genome-wide partitioning algorithm that aims to reduce LD between LD
110 blocks.

111 First, we performed a univariate test for every disease trait at each of the 300 LD blocks to ensure
112 sufficient local genetic signal was present to proceed with bivariate local r_g analyses. Pairs of traits
113 exhibiting a univariate local genetic signal of $p < 0.05/300$ were then carried forward to bivariate
114 tests, resulting in 1,603 bivariate tests across 275 distinct LD blocks. Using a Bonferroni-corrected p-
115 value threshold of $p < 0.05/1,603$, we detected 77 significant bivariate local r_g s across 59 distinct LD

116 blocks, with 25 local r_g s between trait pairs where no significant global r_g was observed (**Figure 1a**,
117 **Figure 1b, Supplementary Table 2, Supplementary Table 3**). These 25 correlations included: (i) local
118 r_g s between all 3 neurodegenerative diseases and SCZ; (ii) a local r_g between PD and BIP; and (ii) 20
119 local r_g s between AD and PD.

120 For 30 of the 77 local r_g s, the genetic signal of both disease traits may overlap entirely, suggested by
121 the upper limit of the 95% confidence interval (CI) for explained variance (i.e. r^2 , the proportion of
122 variance in genetic signal of one disease trait in a pair explained by the other) including 1. Notably,
123 the trait pairs where the upper limit of the 95% CI did not include 1 all involved at least one
124 neurodegenerative disease, with the one exception being a local r_g between PD and SCZ, suggesting
125 that the genetic overlap between neurodegenerative diseases is smaller than between
126 neuropsychiatric disorders in the tested LD blocks (**Figure 1c**).

127

128 **Local analyses associate disease-implicated genomic regions with previously** 129 **unrelated traits**

130 Across the 77 local r_g s, 22 involved trait pairs where both traits had genome-wide significant single
131 nucleotide polymorphisms (SNPs) overlapping the LD block tested, 35 involved trait pairs where one
132 trait in the pair had genome-wide significant SNPs overlapping the LD block tested and 20 involved
133 trait pairs where neither trait had genome-wide significant SNPs overlapping the LD block tested
134 (**Figure 2a**). Thus, despite the targeted nature of our approach (which biased analyses towards LD
135 blocks that contain genome-wide significant GWAS SNPs), 71% of the detected local r_g s linked
136 genomic regions implicated by one of the six disease traits with seemingly unrelated disease traits.

137 For example, LD block 1719 and 2281 both contained genome-wide significant GWAS SNPs from
138 MDD and SCZ, an overlap which was mirrored by a significant local r_g between MDD and SCZ (**Figure**
139 **2b**). In addition, both LD blocks implicated disease traits that did not have overlapping genome-wide
140 significant GWAS SNPs in the region, indicating novel trait associations. These included (i) LBD in LD

141 block 1719, which negatively correlated with SCZ ($\rho = -0.65$, $p = 4.72 \times 10^{-6}$) and (ii) AD and PD, which
142 were positively correlated in LD block 2281 ($\rho = 0.41$, $p = 1.24 \times 10^{-8}$). Notably, both LD blocks
143 contain genes of interest to traits implicated by local r_g analyses, including *DRD2* in LD block 1719
144 (encodes dopamine receptor D2, a target of drugs used in both PD⁷ and SCZ treatment²⁷) and
145 *RAB27B* in LD block 2281 (encodes Rab27b, a Rab GTPase recently implicated in α -synuclein
146 clearance²⁸)

147 Local r_g analyses also highlighted relationships between neurodegenerative traits in regions
148 containing well-known, disease-implicated genes, such as: (i) *SNCA* (implicated in monogenic and
149 sporadic forms of PD^{3,5}) in LD block 681, where a negative local r_g was observed between AD and PD
150 ($\rho = -0.41$, $p = 6.51 \times 10^{-13}$); (ii) *CLU* (associated with sporadic AD^{19,29}) in LD block 1273, where a
151 positive local r_g was observed between AD and PD ($\rho = 0.36$, $p = 8.76 \times 10^{-12}$); and finally, (iii) *APOE*
152 (E4 alleles associated with increased AD risk³⁰) in LD block 2351, where r_g s were observed between
153 LBD and both AD and PD (LBD-AD: $\rho = 0.59$, $p = 1.24 \times 10^{-139}$; LBD-PD: $\rho = -0.29$, $p = 2.75 \times 10^{-7}$)
154 (**Figure 2c**). We also noted a positive correlation between AD and PD in LD block 2128, which
155 contains the AD-associated *KAT8* locus¹⁹ and the PD-associated *SETD1A* locus³. Importantly, while a
156 genetic overlap between AD and PD has been previously reported at the *MAPT* locus (rs393152
157 shown to increase risk of both AD and PD³¹), we were unable to replicate this association due to
158 insufficient univariate signal for AD in the LD block containing *MAPT* (LD block 2207, chr17:
159 43,460,501-44,865,832). In addition, we were unable to replicate a genetic overlap reported
160 between AD and PD in the *HLA* region (specifically in chr6: 31,571,218-32,682,664)³², as several of
161 the overlapping LD blocks (LD block 961-6, ranging across chr6: 31,427,210-32,682,213) had too few
162 overlapping SNPs between the 6 disease traits.

163

164 **Sensitivity analysis indicates that by-proxy cases do not drive spurious local**
165 **correlations among neurodegenerative diseases**

166 Given concerns that UK Biobank (UKBB) by-proxy cases could potentially be mislabelled (i.e. parents
167 of by-proxy case suffered from another type of dementia) and lead to spurious r_g s between
168 neurodegenerative traits, we performed sensitivity analyses using GWASs for AD and PD that
169 excluded UKBB by-proxy cases²⁰. Of the 21 LD blocks where significant local r_g s were observed
170 between the 3 neurodegenerative traits using AD and PD GWASs with by-proxy cases, only 2 (LD
171 block 1273 and 2351) had sufficient local genetic signal for both AD and PD without by-proxy cases.
172 This likely reflects the decrease in cohort numbers when UKBB by-proxy cases are excluded from AD
173 and PD GWASs (**Table 1**). We were able to replicate 2 of the 3 significant local r_g s observed in LD
174 block 1273 and 2351, including the positive r_g between AD and PD in LD block 1273 and the positive
175 r_g between AD and LBD in LD block 2351 (**Supplementary Figure 2, Supplementary Table 4**). Further,
176 while the local r_g between LBD and PD in LD block 2351 was non-significant when using the PD
177 GWAS without by-proxy cases, the correlation was in the same direction in the complementary
178 analysis using the PD GWAS with by-proxy cases (no by-proxy: $\rho = -0.201$, ρ CI = -0.443 to 0.007, $p =$
179 0.061 ; by-proxy: $\rho = -0.293$, ρ CI = -0.405 to -0.184, $p = 2.75 \times 10^{-7}$) (**Supplementary Figure 2,**
180 **Supplementary Table 4**).

181

182 **Local heritability of Lewy body dementia in an APOE-containing LD block is**
183 **only partly explained by Alzheimer's disease and Parkinson's disease**

184 Eleven LD blocks were associated with > 1 trait pair, of which 8 LD blocks had a trait in common
185 across multiple trait pairs. In other words, the genetic component of one disease trait (the outcome
186 trait) could be modelled using the genetic components of multiple predictor disease traits. This
187 included 3 LD blocks (758, 951 and 952) where all 3 neuropsychiatric disorders were significantly
188 correlated with one another, and thus could arguably be the outcome trait. In these situations, each

189 neuropsychiatric disorder was separately modelled as the outcome trait, resulting in 3 independent
190 models within each of these 3 LD blocks. The remaining 5 LD blocks only had 1 trait in common
191 across correlated trait pairs, therefore only one model was constructed for each. A total of 14
192 multivariate models were run across all 8 LD blocks, of which 6 models were found to contain a
193 predictor trait that significantly contributed to the local heritability of an outcome trait (**Figure 3a**,
194 **Supplementary Table 5**).

195 We noted that all models with a neuropsychiatric outcome trait and a significant neuropsychiatric
196 predictor trait had a high multivariate r^2 (range: 0.53-1), with upper confidence intervals including 1
197 (**Figure 3b**), suggesting that the genetic signal of the neuropsychiatric outcome trait could be entirely
198 explained by its predictor traits in these LD blocks. In contrast, in the *APOE*-containing LD block 2351,
199 which was modelled with LBD as the outcome and AD and PD as predictors, the multivariate r^2 was
200 0.43 (95% CI: 0.38 to 0.5), a result that held using GWASs for AD and PD that excluded by-proxy
201 cases ($r^2 = 0.49$, 95% CI: 0.44 to 0.57; **Supplementary Figure 2**). Thus, while AD and PD jointly
202 explained approximately 40% of the local heritability of LBD, a proportion of the local heritability for
203 LBD was independent of AD and PD.

204

205 **Incorporation of gene expression traits to facilitate functional interpretation of** 206 **disease trait correlations**

207 To dissect whether regulation of gene expression might underlie local r_g s between disease traits, we
208 performed local r_g analyses using expression quantitative trait loci (eQTLs) from eQTLGen³³ and
209 PsychENCODE³⁴, which represent large human blood and brain expression datasets, respectively
210 (**Table 1**). We restricted analyses to the 5 LD blocks highlighted in **Figure 2** (LD blocks: 681, 1273,
211 1719, 2281, 2351), which contained genes of interest to at least one of the disease traits implicated
212 by local r_g analyses. From these LD blocks of interest, we defined genic regions (gene start and end
213 coordinates ± 100 kb) for all overlapping protein-coding, antisense or lincRNA genes ($n = 92$).

214 We detected a total of 135 significant bivariate local r_g s across 47 distinct genic regions (FDR < 0.05),
215 with 43 local r_g s across 27 distinct genic regions between trait pairs involving a disease trait and a
216 gene expression trait (**Supplementary Figure 3, Supplementary Table 6**). We noted that the
217 explained variance (r^2) between trait pairs involving a disease trait and a gene expression trait
218 tended to be lower than between trait pairs involving two disease traits (**Supplementary Figure 4**),
219 an observation that aligns with a recent study that found only 11% of trait heritability to be
220 mediated by bulk-tissue gene expression³⁵.

221 With the exception of the *SNCA*-containing LD block 681, where eQTLs for only 1 out of 5 genes
222 tested in the block were correlated with a disease trait (negative r_g between blood-derived *SNCA*
223 eQTLs and PD), the expression of multiple genes was associated with disease traits across the
224 remaining LD blocks (**Figure 4a**). In addition, the expression of several genes was associated with
225 more than one disease trait (**Figure 4b**). For example, blood- and brain-derived *ANKK1* eQTLs (*DRD2*-
226 containing LD block 1719) were negatively correlated with both MDD and SCZ, which themselves
227 were positively correlated (**Figure 4c**). A SNP residing in the coding region of *ANKK1* (rs1800497,
228 commonly known as TaqIA SNP) has been previously associated with alcoholism, schizophrenia and
229 eating disorders, although it is unclear whether this SNP exerts its effect via *DRD2* or *ANKK1*³⁶. As
230 *DRD2* is not expressed in blood, and brain-derived *DRD2* eQTLs did not pass the univariate test for
231 sufficient local genetic signal, we were unable to test for local r_g s between *DRD2* eQTLs and any
232 neuropsychiatric disorder. The data available would therefore suggest that the shared risk of MDD
233 and SCZ in the overlapping *ANKK1* and *DRD2* genic regions may be partly driven by *ANKK1* gene
234 expression.

235 A high degree of eQTL sharing across disease traits was observed in the *CLU*-containing LD block
236 1273, with blood-derived eQTLs from 5 out of the 6 genes implicated in local r_g s found to correlate
237 with both AD and PD (**Figure 4b,d**). This included situations where eQTL-disease trait correlations
238 had (i) the same direction of effect across both disease traits (as observed with *PBK*, *PNOC* and

239 *SCARA5*) or (ii) opposing directions of effect across both disease traits (as observed with *CLU* and
240 *ESCO2*) (**Figure 4d**). Notably, while a significant positive local r_g was observed between AD and PD in
241 the *SCARA5* genic region (reflecting the positive local r_g observed between AD and PD across the
242 entire LD block), no local r_g was observed between AD and PD in the *CLU* genic region, suggesting
243 that the shared risk of AD and PD in LD block 1273 may be driven by the expression of genes other
244 than the AD-associated *CLU* (**Figure 4e**). As a ferritin receptor involved in ferritin internalisation,
245 *SCARA5* could plausibly drive shared AD and PD risk, given that cellular iron overload and iron-
246 induced oxidative stress have been implicated in several neurodegenerative diseases such as AD and
247 PD^{37,38}.

248 Compared to LD block 1273, the degree of eQTL sharing across disease traits was lower in the *APOE*-
249 containing LD block 2351, with eQTLs from 4 out of 16 genes implicated in local r_g s found to
250 correlate with AD and one of PD or LBD (**Figure 4b, f**). Shared eQTL genes were only observed in
251 blood and included *BCL3*, *CLPTM1*, *PVRL2* and *TOMM40*, with expression of *BCL3* and *CLPTM1*
252 positively correlating with AD and PD and expression of *PVRL2* and *TOMM40* positively correlating
253 with AD and LBD. As the exception, *PVR* eQTLs were negatively associated with both AD and PD
254 albeit in different tissues: AD in brain and PD in blood. Expression of the remaining 11 genes was
255 exclusively associated with either AD (n = 8) or PD (n = 3). No significant local r_g was observed
256 between *APOE* eQTLs and AD (FDR < 0.05), although a nominal positive r_g was observed in blood ($\rho =$
257 0.178, ρ CI = 0.007 to 0.352, $p = 0.039$; **Supplementary Figure 3e, Supplementary Table 6**). Overall,
258 these results indicate that risk of neurodegenerative diseases (in particular, AD) is associated with
259 expression of multiple genes in the *APOE*-containing LD block. Further, they add to a growing body
260 of evidence suggesting that in parallel with the well-studied *APOE-ε4* risk allele, there are additional
261 *APOE*-independent risk factors in the region (such as *BCL3*³⁹ and *PVRL2*⁴⁰) that may contribute to AD
262 risk.

263 For a complete overview of all genic regions tested across the 5 LD blocks of interest, see

264 **Supplementary Figure 3** and **Supplementary Table 6**.

265

266 **Discussion**

267 Despite clinical and neuropathological overlaps between neurodegenerative diseases, global
268 analyses of genetic correlation (r_g) show minimal r_g among neurodegenerative diseases or across
269 neurodegenerative and neuropsychiatric diseases. However, local r_g s can deviate from the genome-
270 wide average estimated by global analyses and may even exist in the absence of a genome-wide r_g ,
271 thus motivating the use of tools to model local genetic relations.

272 Here, we applied LAVA to 3 neurodegenerative diseases and 3 neuropsychiatric disorders to
273 determine whether local r_g s exist in a subset of 300 LD blocks that contain genome-wide significant
274 GWAS loci from at least one of six investigated disease traits. We identified 77 significant bivariate
275 local r_g s across 59 distinct LD blocks, with 25 local r_g s between trait pairs where no significant global
276 r_g was observed, including between (i) all 3 neurodegenerative diseases and SCZ and (ii) AD and PD.
277 Local r_g s highlighted expected associations (e.g. AD and LBD in the *APOE*-containing LD block 2351⁵)
278 and putative new associations (e.g. AD and PD in the *CLU*-containing LD block 1273) in genomic
279 regions containing well-known, disease-implicated genes. Likewise, incorporation of eQTLs
280 confirmed known relationships between diseases and genes, such as the association of AD with *CLU*
281 expression²⁹ and PD with *SNCA* expression in blood⁴¹, and revealed putative new disease-gene
282 relationships. Together, these results indicate that more complex aetiological relationships exist
283 between neurodegenerative and neuropsychiatric diseases than those revealed by global r_g s.
284 Further, they highlight potential gene expression intermediaries that may account for local r_g s
285 between disease traits.

286 These findings have important implications for our understanding of neurodegenerative diseases
287 and the extent to which they overlap. An overlap between the synucleinopathies and AD is often
288 acknowledged in the context of LBD, which has been hypothesised to lie on a disease continuum
289 between AD and PD^{5,42}. In support of this continuum, LBD was found to associate with both AD and
290 PD in the *APOE*-containing LD block 2351. Multiple regression analyses confirmed that AD and PD

291 were significant predictors of LBD heritability in LD block 2351. Importantly, when AD and PD were
292 modelled together, they explained only ~ 40% of the local heritability of LBD in LD block 2351,
293 implying that LBD represents more than the union of AD and PD. Further, the associations of AD and
294 PD with LBD had opposing regression coefficients, suggesting that the contribution of AD and PD to
295 LBD in the *APOE* locus may not be synergistic. This mirrors the observation that genome-wide
296 genetic risk scores of AD and PD do not interact in LBD,⁵ and may indicate that different biological
297 pathways underlie the association between LBD and AD/PD. Indeed, only blood-derived *PVRL2* and
298 *TOMM40* eQTLs were found to correlate with both AD and LBD, while no shared eQTL genes were
299 detected between PD and LBD.

300 Less acknowledged is the genetic overlap between AD and PD, with no global r_g reported between
301 the two diseases^{16,43} and no significant evidence for the presence of loci that increase the risk of
302 both diseases⁴⁴. As the exception, genetic overlaps have been reported between AD and PD in the
303 *HLA*³² and *MAPT* loci³¹, hinting that pleiotropy may exist locally. In support of local pleiotropy, we
304 observed 20 local r_g s between AD and PD in genomic regions containing disease-implicated genes,
305 such as *SNCA* (LD block 681) and *CLU* (LD block 1273). In the case of the *CLU*-containing LD block
306 1273, incorporation of eQTLs indicated that the association of AD and PD may be driven by the
307 expression of several genes, including the ferritin receptor *SCARA5*. In contrast, only blood-derived
308 *SNCA* eQTLs were associated with PD in LD block 681, suggesting that the association between AD
309 and PD at the *SNCA* locus could be driven by tissue- or context-dependent gene expression or
310 alternatively other molecular phenotypes.

311 A few studies have demonstrated genetic overlaps between neurodegenerative and
312 neuropsychiatric diseases, such as AD and BIP⁴⁵ as well as AD and MDD⁴⁶, while others have
313 demonstrated no overlap^{16,47}, with divergences in outcomes ascribed to differences in methodology
314 and cohort⁴⁶. Here, we observed a local r_g between BIP and PD, in addition to local r_g s between
315 schizophrenia and all 3 neurodegenerative diseases, which in the case of LBD was observed in an LD

316 block containing the *DRD2*. Notably, parkinsonism in dementia with Lewy bodies (DLB, one of the
317 two LBDs), is often less responsive to dopaminergic treatments than in PD⁴⁸. Furthermore,
318 methylation of the *DRD2* promoter in leukocytes has been shown to differ between DLB and PD⁴⁹,
319 while D2 receptor density has been shown to be significantly reduced in the temporal cortex of DLB
320 patients, but not AD⁵⁰, suggesting that the *DRD2* locus may harbour markers that could distinguish
321 between these neurodegenerative diseases. Our study adds to the body of evidence in favour of a
322 shared genetic basis between neurodegenerative and neuropsychiatric diseases, although further
323 work will be required to determine whether this genetic overlap underlies the clinical and
324 epidemiological links observed between these two disease groups.

325 This study is not without its limitations, with several limitations related to the input data. These
326 limitations include: (i) the variability in cohort size, which in the case of the smallest GWAS, LBD, may
327 explain the limited number of local r_g s observed involving this trait; (ii) the risk of misdiagnosis; and
328 (iii) the lack of genetic diversity (i.e. all traits used were derived from individuals of European
329 ancestry). Given that population-specific genetic risk factors exist, such as the lack of *MAPT* GWAS
330 signal in the largest GWAS of Asian patients with PD⁵¹, and that transethnic global r_g s between traits
331 such as gene expression are significantly less than 1⁵², it is imperative that studies of local r_g are
332 expanded to include diverse populations.

333 Among methodological limitations, both LDSC and LAVA only consider autosomal chromosomes,
334 leaving out chromosome X, which is not only longer than chromosome 8-22, but also encodes 858
335 and 689 protein-coding and non-coding genes, respectively (Ensembl v106)⁵³. Furthermore, as
336 mentioned by the developers of LAVA¹⁸, local r_g s could potentially be confounded by association
337 signals from adjacent genomic regions, a limitation which is particularly pertinent in our analysis of
338 gene expression traits where LD blocks were divided into smaller (often overlapping) genic regions.

339 Importantly, as with any genetic correlation analysis, an observed r_g does not guarantee the
340 presence of true pleiotropy. Spurious r_g s can occur due to LD or misclassification¹⁷. Here, we

341 attempted to address the potential misclassification of by-proxy cases via sensitivity analyses using
342 GWASs for AD and PD that excluded UKBB by-proxy cases. We replicated 2 of the 3 significant local
343 r_g s observed in 2 LD blocks when using GWASs with by-proxy cases. However, we were unable to
344 test for local r_g s across the remaining 19 LD blocks due to insufficient univariate signal, which could
345 reflect (i) a genuine contribution of by-proxy cases to trait h^2 in the region or (ii) a lack of statistical
346 power to detect a genetic signal. Given the substantial decrease in cohort numbers when UKBB by-
347 proxy cases are excluded from AD and PD GWASs (**Table 1**), a lack of statistical power seems the
348 more likely explanation, warranting a revisit of this analysis as clinically-diagnosed and/or
349 pathologically-defined cohorts increase in size.

350 Finally, even where observed r_g s potentially represent true pleiotropy, LAVA cannot discriminate
351 between vertical and horizontal pleiotropy (also known as mediated and biological pleiotropy,
352 respectively^{17,18}). Thus, while incorporation of gene expression can provide testable hypotheses
353 regarding the underlying genes and biological pathways that drive relationships between
354 neurodegenerative and neuropsychiatric diseases, experimental validation is required to establish
355 the extent to which these genes represent genuine intermediary phenotypes.

356 In summary, our results have important implications for our understanding of the genetic
357 architecture of neurodegenerative and neuropsychiatric diseases, including the demonstration of
358 local pleiotropy particularly between neurodegenerative diseases. Not only do these findings suggest
359 that neurodegenerative diseases may share common pathogenic processes, highlighting putative
360 gene expression intermediaries which may underlie relationships between diseases, but they also
361 infer the existence of common therapeutic targets across neurodegenerative diseases that could be
362 leveraged for the benefit of broader patient groups.

363 **Materials and methods**

364 **Trait pre-processing**

365 GWAS summary statistics from a total of 8 distinct traits were used, including 6 disease traits and 2
366 gene expression traits. Gene expression traits were used to facilitate functional interpretation of
367 local genetic correlations (r_g) between disease traits. Disease traits included 3 neurodegenerative
368 diseases (Alzheimer's disease, AD; Lewy body dementia, LBD; and Parkinson's disease, PD) and 3
369 neuropsychiatric disorders (bipolar disorder, BIP; major depressive disorder, MDD; and
370 schizophrenia, SCZ)^{3,19–23,54}. Gene expression traits included expression quantitative trait loci (eQTLs)
371 from eQTLGen³³ and PsychENCODE³⁴, which represent large human blood and brain expression
372 datasets, respectively. All traits used were derived from individuals of European ancestry. Details of
373 all summary statistics used can be found in **Table 1**. Where necessary, SNP genomic coordinates
374 were mapped to Reference SNP cluster IDs (rsIDs) using the SNPlocs.Hsapiens.dbSNP144.GRCh37
375 package⁵⁵. In the case of the PD GWAS without UK Biobank (UKBB) data (summary statistics were
376 kindly provided by the International Parkinson Disease Genomics Consortium), additional quality
377 control filtering was applied, including removal of SNPs (i) with MAF < 1%, (ii) displaying an I²
378 heterogeneity value of ≥ 80 and (iii) where the SNP was not present in at least 9 out of the 13
379 cohorts included in the meta-analysis.

380

381 **Global genetic correlation analysis and estimation of sample overlaps**

382 Across disease trait pairs, LD score regression (LDSC) was used to (i) determine the global r_g and (ii)
383 estimate sample overlap^{56,57}. The latter was used as an input for LAVA, given that potential sample
384 overlap between GWASs could impact estimated local r_g s¹⁸. Summary statistics for each trait were
385 pre-processed using LDSC's `munge_sumstats.py`
386 (https://github.com/bulik/ldsc/blob/master/munge_sumstats.py) together with HapMap Project
387 Phase 3 SNPs⁵⁸. For the LD reference panel, 1000 Genomes Project Phase 3 European population

388 SNPs were used⁵⁹. Both HapMap Project Phase 3 SNPs and European LD Scores from the 1000
389 Genomes Project are made available by the developers of LDSC^{56,57} from the following repository:
390 <https://alkesgroup.broadinstitute.org/LDSCORE/> (see **Key resources** for details). Any shared
391 variance due to sample overlap was modelled as a residual genetic covariance. As performed by
392 Werme *et al.*¹⁸, a symmetric matrix was constructed, with off-diagonal elements populated by the
393 intercepts for genetic covariance derived from cross-trait LDSC and diagonal elements populated by
394 comparisons of each phenotype with itself. This symmetric matrix was then converted to a
395 correlation matrix. Importantly, it is not possible to estimate sample overlap with eQTL summary
396 statistics, but given that the cohorts used in the GWASs were different from the cohorts included in
397 the eQTL datasets, we assumed sample overlap between GWASs and eQTL datasets to be negligible.
398 Thus, they were set to 0 in the correlation matrix. However, given the inclusion of GTEx samples in
399 both eQTL datasets and our inability to estimate this overlap, downstream LAVA analyses were
400 performed separately for each eQTL dataset.

401

402 **Defining genomic regions for local genetic correlation analysis**

403 **Between disease traits**

404 Genome-wide significant loci ($p < 5 \times 10^{-8}$) were derived from publicly available AD, BIP, LBD, MDD,
405 PD and SCZ GWASs. Genome-wide significant loci were overlapped with linkage disequilibrium (LD)
406 blocks generated by Werme *et al.*¹⁸ using a genome-wide partitioning algorithm. Briefly, each
407 chromosome was recursively split into blocks using (i) a break point to minimise LD between the
408 resulting blocks and (ii) a minimum size requirement. The resulting LD blocks represent
409 approximately equal-sized, semi-independent blocks of SNPs, with a minimum size requirement of
410 2,500 SNPs (resulting in an average block size of around 1Mb). Only those LD blocks containing
411 genome-wide significant GWAS loci from at least one trait were carried forward in downstream
412 analyses, resulting in a total of 300 autosomal LD blocks. Of the 22 possible autosomes, 21 contained

413 LD blocks with overlapping loci, with the highest number of LD blocks located in chromosome 1 and
414 6 (Supplementary Figure 1).

415 **Between disease and gene expression traits**

416 A total of 5 LD blocks, as highlighted by bivariate local r_g analysis of disease traits, were used in this
417 analysis (LD block 681, 1273, 1719, 2281 and 2351). From these LD blocks of interest, we defined
418 genic regions for all protein-coding, antisense or lincRNA genes that overlapped an LD block of
419 interest. Most lead *cis*-eQTL SNPs (i.e. the SNP with the most significant p-value in a SNP-gene
420 association) lie outside the gene start and end coordinates and are located within 100 kb of the
421 gene. Indeed, in eQTLGen, 55% of lead-eQTL SNPs were outside the gene body and 92% were within
422 100 kb from the gene³³. Thus, we extended genic regions with a 100-kb window (100 kb upstream
423 and 100 kb downstream of gene coordinates). These genic regions ($n = 92$) were carried forward in
424 downstream analyses.

425

426 **Estimating bivariate local genetic correlations**

427 **Between disease traits**

428 The detection of valid and interpretable local r_g requires the presence of sufficient local genetic
429 signal. For this reason, a univariate test was performed as a filtering step for bivariate local
430 r_g analyses. Bivariate local r_g analyses were only performed for pairs of disease traits which both
431 exhibited a significant univariate local genetic signal ($p < 0.05/300$, where the denominator
432 represents the total number of tested LD blocks). This step resulted in a total of 1,603 bivariate tests
433 spanning 275 distinct LD blocks. Bivariate results were considered significant when $p < 0.05/1603$.

434 **Between disease and gene expression traits**

435 For each genic region, only those disease traits that were found to have significant local r_g in the
436 associated LD block were carried forward to univariate and bivariate analyses with eQTL summary
437 statistics. As previously described, a univariate test was performed as a filtering step for bivariate
438 local $r_{g,g}$ analyses. Thus, bivariate local r_g analyses were only performed (i) if the gene expression

439 trait (i.e. eQTL genes) exhibited a significant univariate local genetic signal and (ii) for pairs of traits
440 (disease and gene expression) which both exhibited a significant univariate local genetic signal. A
441 cut-off of $p < 0.05/92$ (the denominator represents the total number of tested genic regions) was
442 used to determine univariate significance. A 100-kb window resulted in a total of 354 bivariate tests
443 spanning 55 distinct genic regions. Bivariate results were corrected for multiple testing using two
444 strategies: (i) a more lenient FDR correction and (ii) a more stringent Bonferroni correction ($p <$
445 $0.05/n_{\text{tests}}$, where the denominator represents the total number of bivariate tests). We discuss
446 results passing $FDR < 0.05$, but we make the results of both correction strategies available
447 (**Supplementary Table 6, Supplementary Table 7**).

448 We evaluated the effect of window size on bivariate correlations by re-running all analyses using a
449 50-kb window. Following filtering for significant univariate local genetic signal (as described above),
450 a total of 267 bivariate tests were run spanning 50 distinct genic regions. We detected 110
451 significant bivariate local r_g s ($FDR < 0.05$), 83 of which were also significant when using a 100-kb
452 window (**Supplementary Figure 5**). We observed strong positive Pearson correlations in local r_g
453 coefficient and p-value estimates across the two window sizes, indicating that our results are robust
454 to the choice of window size (**Supplementary Figure 5**). Of note, p-value estimates between disease
455 and gene expression traits tended to be lower when using the 50-kb window, as compared to the
456 100-kb window, as evidenced by the fitted line falling below the equivalent of $y = x$. This observation
457 may be a reflection of stronger *cis*-eQTLs tending to have a smaller distance between SNP and
458 gene³³. In contrast, p-value estimates between two disease traits were comparable across the two
459 window sizes.

460

461 **Local multiple regression**

462 For LD blocks with significant bivariate local r_g between one disease trait and ≥ 2 disease traits,
463 multiple regression was used to determine the extent to which the genetic component of the

464 outcome trait could be explained by the genetic components of multiple predictor traits. These
465 analyses permitted exploration of the independent effects of predictor traits on the outcome trait. A
466 predictor trait was considered significant when $p < 0.05$.

467

468 **Sensitivity analysis using by-proxy cases**

469 As UK Biobank (UKBB) by-proxy cases could potentially be mislabelled (i.e. parent of by-proxy case
470 suffered from another type of dementia) and lead to spurious r_g s between neurodegenerative traits,
471 we performed replication analyses using GWASs for AD²⁰ and PD that excluded UKBB by-proxy cases.
472 LD blocks were filtered to include only those where significant bivariate local r_g s were observed
473 between LBD and either by-proxy AD or by-proxy PD GWASs, in addition to between by-proxy AD
474 and by-proxy PD GWASs. These criteria limited the number of LD blocks to 21. Bivariate local
475 correlations were only performed for pairs of traits which both exhibited a significant univariate local
476 genetic signal ($p < 0.05/21$, where the denominator represents the total number of tested loci),
477 which resulted in a total of 10 bivariate tests spanning 6 distinct loci. We additionally performed
478 multiple regression in LD block 2351 using LBD as the outcome and AD and PD (both excluding UKBB
479 by-proxy cases) as predictors. A predictor trait was considered significant when $p < 0.05$.

480

481 **R packages**

482 All analyses were performed in R (v 4.0.5)⁶⁰. As indicated in the accompanying GitHub repository
483 (<https://github.com/RHReynolds/neurodegen-psych-local-corr>), all relevant packages were sourced
484 from CRAN, Bioconductor (via BiocManager⁶¹) or directly from GitHub. Figures were produced using
485 *circlize*, *ggplot2* and *ggraph*⁶²⁻⁶⁴. All open-source software used in this paper is listed in **Key**
486 **resources**.

487

488 **Code availability**

489 Code used to pre-process GWASs, run genetic correlation analyses and to generate figures for the
490 manuscript are available at: <https://github.com/RHReynolds/neurodegen-psych-local-corr>
491 (doi:[10.5281/zenodo.6587707](https://doi.org/10.5281/zenodo.6587707)). All other open-source software used in this paper is listed in **Key**
492 **resources**.

493

494 **Data availability**

495 Analyses in this study relied on publicly available data, all of which are listed in **Key resources**. In the
496 case of the PD GWAS without UK Biobank (UKBB) data, summary statistics were kindly provided by
497 the International Parkinson Disease Genomics Consortium: <https://pdgenetics.org/>.

498

499 **Key resources**

Resource	Source/Reference	Identifier/URL
Deposited Data		
Ensembl GRCh37 Ensembl v87	Ensembl genome browser ⁵³	http://ftp.ensembl.org/pub/grch37/current/gtf/homo_sapiens/
eQTLGen eQTLs	Vosã <i>et al.</i> , 2021 ³³	https://www.eqtngen.org/cis-eqtls.html
GWAS, Alzheimer's disease (clinically diagnosed + UK Biobank proxy cases and controls)	Jansen <i>et al.</i> , 2019 ¹⁹	https://ctg.cncr.nl/software/summary-statistics
GWAS, Alzheimer's disease (clinically diagnosed)	Kunkle <i>et al.</i> , 2019 ²⁰	https://www.niagads.org/igap-rv-summary-stats-kunkle-p-value-data
GWAS, Bipolar disease	Mullins <i>et al.</i> , 2021 ²²	https://www.med.unc.edu/pgc/download-results/
GWAS, Lewy body dementia	Chia <i>et al.</i> , 2021 ⁵	https://www.ebi.ac.uk/gwas/studies/GCST90001390
GWAS, Parkinson's disease excluding 23andMe	Nalls <i>et al.</i> , 2019 ³	https://pdgenetics.org/resources
GWAS, Major depressive disorder	Howard <i>et al.</i> , 2019 ²¹	https://www.med.unc.edu/pgc/download-results/
GWAS, Schizophrenia	Pardiñas <i>et al.</i> , 2018 ²³	https://www.med.unc.edu/pgc/download-results/
LAVA LD blocks	Werme <i>et al.</i> , 2021 ¹⁸	https://github.com/cadeleeuw/lava-partitioning

LDSC: HapMap Project Phase 3 SNPs	International HapMap 3 Consortium ⁵⁸	https://alkesgroup.broadinstitute.org/LDSCORE/ ; file name: w_hm3_snplist
LDSC: 1000 Genomes European LD Scores	1000 Genomes Project Consortium ⁵⁹	https://alkesgroup.broadinstitute.org/LDSCORE/ ; file name: eur_w_ld_chr.tar.bz2
PsychENCODE eQTLs	Wang <i>et al.</i> , 2018 ³⁴	http://resource.psychencode.org/
Software		
Bioconductor		http://www.bioconductor.org ; RRID:SCR_006442
BiocManager (v 1.30.16)	Morgan, 2021 ⁶¹	https://CRAN.R-project.org/package=BiocManager
CRAN		http://cran.r-project.org/ ; RRID:SCR_003005
circlize (v 0.4.13)	Gu <i>et al.</i> , 2014 ⁶²	https://github.com/jokergoo/circlize ; RRID:SCR_002141
cowplot (v 1.1.1)	Wilke, 2020 ⁶⁵	https://CRAN.R-project.org/package=cowplot ; RRID:SCR_018081
data.table (v 1.14.2)	Dowle and Srinivasan, 2021 ⁶⁶	https://CRAN.R-project.org/package=data.table
doSNOW (v 1.0.19)	Microsoft and Weston, 2020 ⁶⁷	https://CRAN.R-project.org/package=doSNOW
foreach (v 1.5.1)	Microsoft and Weston, 2020 ⁶⁸	https://CRAN.R-project.org/package=foreach
GenomicRanges (v 1.42.0)	Lawrence <i>et al.</i> , 2013 ⁶⁹	https://bioconductor.org/packages/release/bioc/html/GenomicRanges.html ; RRID:SCR_000025
ggbeeswarm (v 0.6.0)	Clarke and Sherrill-Mix, 2017 ⁷⁰	https://CRAN.R-project.org/package=ggbeeswarm
ggplot2 (v 3.3.5)	Wickham, 2016 ⁶³	https://ggplot2.tidyverse.org ; RRID:SCR_014601
ggpubr (v 0.4.0)	Kassambara, 2020 ⁷¹	https://CRAN.R-project.org/package=ggpubr ; RRID:SCR_021139
ggraph (v 2.0.5)	Pedersen, 2021 ⁶⁴	https://CRAN.R-project.org/package=ggraph ; RRID:SCR_021239
gtools (v 3.9.2)	Warnes <i>et al.</i> , 2021 ⁷²	https://CRAN.R-project.org/package=gtools
here (v 1.0.1)	Müller, 2020 ⁷³	https://CRAN.R-project.org/package=here
janitor (v 2.1.0)	Firke, 2021 ⁷⁴	https://CRAN.R-project.org/package=janitor

LAVA (v 0.0.6; commit #7be342)	Werme <i>et al.</i> , 2021 ¹⁸	https://github.com/josefin-werme/LAVA
LDSC (v 1.0.1)	Bulik-Sullivan <i>et al.</i> , 2015 ⁷⁵	https://github.com/bulik/ldsc
openxlsx (v 4.2.4)	Schauberger and Walker, 2021 ⁷⁶	https://CRAN.R-project.org/package=openxlsx ; RRID:SCR_019185
qdapTools (v 1.3.5)	Rinker, 2015 ⁷⁷	http://github.com/trinker/qdapTools
readxl (v 1.3.1)	Wickham and Bryan, 2019 ⁷⁸	https://CRAN.R-project.org/package=readxl ; RRID:SCR_018083
R (v 4.0.5)	R Core Team ⁶⁰	http://www.r-project.org/ ; RRID:SCR_001905
rtracklayer (v 1.50.0)	Lawrence <i>et al.</i> , 2009 ⁷⁹	https://bioconductor.org/packages/release/bioc/html/rtracklayer.html ; RRID:SCR_021325
tidyverse (v 1.3.1)	Wickham <i>et al.</i> , 2019 ⁸⁰	https://www.tidyverse.org/ ; RRID:SCR_019186

500

501 **Acknowledgements**

502 We are grateful to Dr Cornelis Blauwendraat for feedback throughout this project. We would also
503 like to thank the scientific community behind all the GWAS datasets, as well as data scientists
504 developing the above-mentioned analysis tools, for making them publicly available and thus
505 enabling the completion of this study.

506

507 **Funding**

508 This research was funded in whole or in part by Aligning Science Across Parkinson's [Grant numbers:
509 ASAP-000478 and ASAP-000509] through the Michael J. Fox Foundation for Parkinson's Research
510 (MJFF). For the purpose of open access, the author has applied a CC BY public copyright license to all
511 Author Accepted Manuscripts arising from this submission.

512 AZW was supported through the award of a Clinical Research Fellowship funded by Eisai, Ltd and the
513 Wolfson Foundation. SWS was supported in part by the Intramural Research Program of the U.S.
514 National Institutes of Health (National Institute of Neurological Disorders and Stroke; project
515 number: 1Z1ANS003154). SAGT was supported by a Fonds de Recherche du Québec – Santé Junior 1
516 Award and by operational funds from the Institut de valorisation des données (IVADO). MR was
517 supported through the award of a UKRI Medical Research Council Clinician Scientist Fellowship (MRC
518 Grant Code: MR/N008324/1). JH was supported through the UKRI Medical Research Council (MRC
519 Grant Code: MR/N026004/), the UK Dementia Research Institute, the Dolby Family Fund, and the
520 National Institute for Health Research University College London Hospitals Biomedical Research
521 Centre.

522

523

524 **Author contributions**

525 RHR, SAGT and MR conceived and designed the study. RHR and AZW analysed data and drafted the
526 figures. FLD, MS and SAGT consulted on the statistical analysis. SWS and MR provided clinical insight
527 to data interpretation. RHR wrote the initial manuscript. All authors contributed to the critical
528 analysis and revision of the manuscript.

529

530 **Competing interests**

531 AZW served as a medical monitor for Neuroscience Trials Australia, receiving no personal
532 compensation. SWS serves on the scientific advisory council of the Lewy Body Dementia Association
533 and receives grant support from Cerevel Therapeutics.

534 **References**

- 535 1. Robinson, J.L., Lee, E.B., Xie, S.X., Rennert, L., Suh, E., Bredenberg, C., Caswell, C., Van Deerlin,
536 V.M., Yan, N., Yousef, A., et al. (2018). Neurodegenerative disease concomitant proteinopathies are
537 prevalent, age-related and APOE4-associated. *Brain* *141*, 2181–2193.
- 538 2. De Jager, P.L., Yang, H.-S., and Bennett, D.A. (2018). Deconstructing and targeting the genomic
539 architecture of human neurodegeneration. *Nat. Neurosci.* *21*, 1310–1317.
- 540 3. Nalls, M.A., Blauwendraat, C., Vallerga, C.L., Heilbron, K., Bandres-Ciga, S., Chang, D., Tan, M., Kia,
541 D.A., Noyce, A.J., Xue, A., et al. (2019). Identification of novel risk loci, causal insights, and heritable
542 risk for Parkinson’s disease: a meta-analysis of genome-wide association studies. *Lancet. Neurol.* *18*,
543 1091–1102.
- 544 4. Guerreiro, R., Ross, O.A., Kun-Rodrigues, C., Hernandez, D.G., Orme, T., Eicher, J.D., Shepherd,
545 C.E., Parkkinen, L., Darwent, L., Heckman, M.G., et al. (2018). Investigating the genetic architecture
546 of dementia with Lewy bodies: a two-stage genome-wide association study. *Lancet Neurol.* *17*, 64–
547 74.
- 548 5. Chia, R., Sabir, M.S., Bandres-Ciga, S., Saez-Atienzar, S., Reynolds, R.H., Gustavsson, E., Walton,
549 R.L., Ahmed, S., Viollet, C., Ding, J., et al. (2021). Genome sequencing analysis identifies new loci
550 associated with Lewy body dementia and provides insights into its genetic architecture. *Nat. Genet.*
551 *53*, 294–303.
- 552 6. Masters, C.L., Bateman, R., Blennow, K., Rowe, C.C., Sperling, R.A., and Cummings, J.L. (2015).
553 Alzheimer’s disease. *Nat. Rev. Dis. Prim.* *1*, 15056.
- 554 7. Poewe, W., Seppi, K., Tanner, C.M., Halliday, G.M., Volkman, J., Schrag, A., Lang, A.E., Brundin, P.,
555 Volkman, J., Schrag, A., et al. (2017). Parkinson disease. *Nat. Rev. Dis. Prim.* *3*, 17013.
- 556 8. Kuring, J.K., Mathias, J.L., and Ward, L. (2018). Prevalence of Depression, Anxiety and PTSD in
557 People with Dementia: a Systematic Review and Meta-Analysis. *Neuropsychol. Rev.* *28*, 393–416.

- 558 9. Reijnders, J.S.A.M., Ehrt, U., Weber, W.E.J., Aarsland, D., and Leentjens, A.F.G. (2008). A
559 systematic review of prevalence studies of depression in Parkinson's disease. *Mov. Disord.* *23*, 183–
560 189; quiz 313.
- 561 10. Weintraub, D., Aarsland, D., Chaudhuri, K.R., Dobkin, R.D., Leentjens, A.F., Rodriguez-Violante,
562 M., and Schrag, A. (2022). The neuropsychiatry of Parkinson's disease: advances and challenges.
563 *Lancet Neurol.* *21*, 89–102.
- 564 11. Ribe, A.R., Laursen, T.M., Charles, M., Katon, W., Fenger-Grøn, M., Davydow, D., Chwastiak, L.,
565 Cerimele, J.M., and Vestergaard, M. (2015). Long-term risk of dementia in persons with
566 schizophrenia: A danish population-based cohort study. *JAMA Psychiatry* *72*, 1095–1101.
- 567 12. Stroup, T.S., Olfson, M., Huang, C., Wall, M.M., Goldberg, T., Devanand, D.P., and Gerhard, T.
568 (2021). Age-Specific Prevalence and Incidence of Dementia Diagnoses among Older US Adults with
569 Schizophrenia. *JAMA Psychiatry* *78*, 632–641.
- 570 13. Gustafsson, H., Nordström, A., and Nordström, P. (2015). Depression and subsequent risk of
571 Parkinson disease A nationwide cohort study. *Neurology* *84*, 2422–2429.
- 572 14. Kazmi, H., Walker, Z., Booij, J., Khan, F., Shah, S., Sudre, C.H., Buckman, J.E.J., and Schrag, A.E.
573 (2021). Late onset depression: Dopaminergic deficit and clinical features of prodromal Parkinson's
574 disease: A cross-sectional study. *J. Neurol. Neurosurg. Psychiatry* *92*, 158–164.
- 575 15. Bellou, E., Stevenson-Hoare, J., and Escott-Price, V. (2020). Polygenic risk and pleiotropy in
576 neurodegenerative diseases. *Neurobiol. Dis.* *142*, 104953.
- 577 16. Brainstorm Consortium, Anttila, V., Bulik-Sullivan, B., Finucane, H.K., Walters, R.K., Bras, J.,
578 Duncan, L., Escott-Price, V., Falcone, G.J., Gormley, P., et al. (2018). Analysis of shared heritability in
579 common disorders of the brain. *Science* *360*, eaap8757.
- 580 17. van Rheenen, W., Peyrot, W.J., Schork, A.J., Lee, S.H., and Wray, N.R. (2019). Genetic correlations
581 of polygenic disease traits: from theory to practice. *Nat. Rev. Genet.* *20*, 567–581.

- 582 18. Werme, J., van der Sluis, S., Posthuma, D., and de Leeuw, C.A. (2022). An integrated framework
583 for local genetic correlation analysis. *Nat. Genet.* *54*, 274–282.
- 584 19. Jansen, I.E., Savage, J.E., Watanabe, K., Bryois, J., Williams, D.M., Steinberg, S., Sealock, J.,
585 Karlsson, I.K., Hägg, S., Athanasiu, L., et al. (2019). Genome-wide meta-analysis identifies new loci
586 and functional pathways influencing Alzheimer’s disease risk. *Nat. Genet.* *51*, 404–413.
- 587 20. Kunkle, B.W., Grenier-Boley, B., Sims, R., Bis, J.C., Damotte, V., Naj, A.C., Boland, A., Vronskaya,
588 M., van der Lee, S.J., Amlie-Wolf, A., et al. (2019). Genetic meta-analysis of diagnosed Alzheimer’s
589 disease identifies new risk loci and implicates A β , tau, immunity and lipid processing. *Nat. Genet.* *51*,
590 414–430.
- 591 21. Howard, D.M., Adams, M.J., Clarke, T.K., Hafferty, J.D., Gibson, J., Shiralil, M., Coleman, J.R.I.,
592 Hagenaaars, S.P., Ward, J., Wigmore, E.M., et al. (2019). Genome-wide meta-analysis of depression
593 identifies 102 independent variants and highlights the importance of the prefrontal brain regions.
594 *Nat. Neurosci.* *22*, 343–352.
- 595 22. Mullins, N., Forstner, A.J., O’Connell, K.S., Coombes, B., Coleman, J.R.I., Qiao, Z., Als, T.D., Bigdeli,
596 T.B., Børte, S., Bryois, J., et al. (2021). Genome-wide association study of more than 40,000 bipolar
597 disorder cases provides new insights into the underlying biology. *Nat. Genet.* *53*, 817–829.
- 598 23. Pardiñas, A.F., Holmans, P., Pocklington, A.J., Escott-Price, V., Ripke, S., Carrera, N., Legge, S.E.,
599 Bishop, S., Cameron, D., Hamshere, M.L., et al. (2018). Common schizophrenia alleles are enriched in
600 mutation-intolerant genes and in regions under strong background selection. *Nat. Genet.* *50*, 381–
601 389.
- 602 24. GBD 2019 Diseases and Injuries Collaborators (2020). Global burden of 369 diseases and injuries
603 in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease
604 Study 2019. *Lancet (London, England)* *396*, 1204–1222.
- 605 25. Poewe, W., Seppi, K., Tanner, C.M., Halliday, G.M., Brundin, P., Volkman, J., Schrag, A.-E., and

- 606 Lang, A.E. (2017). Parkinson disease. *Nat. Rev. Dis. Prim.* **3**, 17013.
- 607 26. Erkkinen, M.G., Kim, M., and Geschwind, M.D. (2018). Clinical Neurology and Epidemiology of the
608 Major Neurodegenerative Diseases. *Cold Spring Harb. Perspect. Biol.* **10**,
- 609 27. Urs, N.M., Peterson, S.M., and Caron, M.G. (2017). New Concepts in Dopamine D2Receptor
610 Biased Signaling and Implications for Schizophrenia Therapy. *Biol. Psychiatry* **81**, 78–85.
- 611 28. Underwood, R., Wang, B., Carico, C., Whitaker, R.H., Placzek, W.J., and Yacoubian, T.A. (2020).
612 The GTPase Rab27b regulates the release, autophagic clearance, and toxicity of α -synuclein. *J. Biol.*
613 *Chem.* **295**, 8005–8016.
- 614 29. Foster, E.M., Dangla-Valls, A., Lovestone, S., Ribe, E.M., and Buckley, N.J. (2019). Clusterin in
615 Alzheimer’s Disease: Mechanisms, Genetics, and Lessons From Other Pathologies. *Front. Neurosci.*
616 **13**, 164.
- 617 30. Bertram, L., McQueen, M.B., Mullin, K., Blacker, D., and Tanzi, R.E. (2007). Systematic meta-
618 analyses of Alzheimer disease genetic association studies: The AlzGene database. *Nat. Genet.* **39**,
619 17–23.
- 620 31. Desikan, R.S., Schork, A.J., Wang, Y., Witoelar, A., Sharma, M., McEvoy, L.K., Holland, D., Brewer,
621 J.B., Chen, C.H., Thompson, W.K., et al. (2015). Genetic overlap between Alzheimer’s disease and
622 Parkinson’s disease at the MAPT locus. *Mol. Psychiatry* **20**, 1588–1595.
- 623 32. Stolp Andersen, M., Tan, M., Holtman, I.R., Hardy, J., and Pihlstrøm, L. (2022). Dissecting the
624 limited genetic overlap of Parkinson’s and Alzheimer’s disease. *Ann. Clin. Transl. Neurol.* 1–7.
- 625 33. Vösa, U., Claringbould, A., Westra, H.J., Bonder, M.J., Deelen, P., Zeng, B., Kirsten, H., Saha, A.,
626 Kreuzhuber, R., Yazar, S., et al. (2021). Large-scale cis- and trans-eQTL analyses identify thousands of
627 genetic loci and polygenic scores that regulate blood gene expression. *Nat. Genet.* **53**, 1300–1310.
- 628 34. Wang, D., Liu, S., Warrell, J., Won, H., Shi, X., Navarro, F.C.P., Clarke, D., Gu, M., Emani, P., Yang,
629 Y.T., et al. (2018). Comprehensive functional genomic resource and integrative model for the human

- 630 brain. *Science* 362,.
- 631 35. Yao, D.W., O'Connor, L.J., Price, A.L., and Gusev, A. (2020). Quantifying genetic effects on disease
632 mediated by assayed gene expression levels. *Nat. Genet.* 52, 626–633.
- 633 36. Ponce, G., Pérez-González, R., Aragüés, M., Palomo, T., Rodríguez-Jiménez, R., Jiménez-Arriero,
634 M.A., and Hoenicka, J. (2009). The ANKK1 kinase gene and psychiatric disorders. *Neurotox. Res.* 16,
635 50–59.
- 636 37. Li, J.Y., Paragas, N., Ned, R.M., Qiu, A., Viltard, M., Leete, T., Drexler, I.R., Chen, X., Sanna-Cherchi,
637 S., Mohammed, F., et al. (2009). Scara5 Is a Ferritin Receptor Mediating Non-Transferrin Iron
638 Delivery. *Dev. Cell* 16, 35–46.
- 639 38. Crielaard, B.J., Lammers, T., and Rivella, S. (2017). Targeting iron metabolism in drug discovery
640 and delivery. *Nat. Rev. Drug Discov.* 16, 400–423.
- 641 39. Nho, K., Kim, S., Horgusluoglu, E., Risacher, S.L., Shen, L., Kim, D., Lee, S., Foroud, T., Shaw, L.M.,
642 Trojanowski, J.Q., et al. (2017). Association analysis of rare variants near the APOE region with CSF
643 and neuroimaging biomarkers of Alzheimer's disease. *BMC Med. Genomics* 10,.
- 644 40. Zhou, X., Chen, Y., Mok, K.Y., Kwok, T.C.Y., Mok, V.C.T., Guo, Q., Ip, F.C., Chen, Y., Mullapudi, N.,
645 Weiner, M.W., et al. (2019). Non-coding variability at the APOE locus contributes to the Alzheimer's
646 risk. *Nat. Commun.* 10, 1–16.
- 647 41. Locascio, J.J., Eberly, S., Liao, Z., Liu, G., Hoising, A.N., Duong, K., Trisini-Lipsanopoulos, A.,
648 Dhima, K., Hung, A.Y., Flaherty, A.W., et al. (2015). Association between α -synuclein blood
649 transcripts and early, neuroimaging-supported Parkinson's disease. *Brain* 138, 2659–2671.
- 650 42. Jellinger, K.A. (2018). Dementia with Lewy bodies and Parkinson's disease-dementia: current
651 concepts and controversies. *J. Neural Transm.* 125, 615–650.
- 652 43. Guerreiro, R., Escott-Price, V., Darwent, L., Parkkinen, L., Ansorge, O., Hernandez, D.G., Nalls,
653 M.A., Clark, L., Honig, L., Marder, K., et al. (2016). Genome-wide analysis of genetic correlation in

- 654 dementia with Lewy bodies, Parkinson's and Alzheimer's diseases. *Neurobiol. Aging* *38*, 214.e7-
655 214.e10.
- 656 44. Moskvin, V., Harold, D., Russo, G.C., Vedernikov, A., Sharma, M., Saad, M., Holmans, P., Bras,
657 J.M., Bettella, F., Keller, M.F., et al. (2013). Analysis of genome-wide association studies of alzheimer
658 disease and of parkinson disease to determine if these 2 diseases share a common genetic risk.
659 *JAMA Neurol.* *70*, 1268–1276.
- 660 45. Drange, O.K., Bjerkeheggen Smeland, O., Shadrin, A.A., Finseth, P.I., Witoelar, A., Frei, O., Wang,
661 Y., Hassani, S., Djurovic, S., Dale, A.M., et al. (2019). Genetic overlap between alzheimer's disease
662 and bipolar disorder implicates the MARK2 and VAC14 genes. *Front. Neurosci.* *13*, 1–11.
- 663 46. Lutz, M.W., Sprague, D., Barrera, J., and Chiba-Falek, O. (2020). Shared genetic etiology
664 underlying Alzheimer's disease and major depressive disorder. *Transl. Psychiatry* *10*,
- 665 47. Gibson, J., Russ, T.C., Adams, M.J., Clarke, T.K., Howard, D.M., Hall, L.S., Fernandez-Pujals, A.M.,
666 Wigmore, E.M., Hayward, C., Davies, G., et al. (2017). Assessing the presence of shared genetic
667 architecture between Alzheimer's disease and major depressive disorder using genome-wide
668 association data. *Transl. Psychiatry* *7*,
- 669 48. McKeith, I.G., Boeve, B.F., Dickson, D.W., Halliday, G., Taylor, J.-P., Weintraub, D., Aarsland, D.,
670 Galvin, J., Attems, J., Ballard, C.G., et al. (2017). Diagnosis and management of dementia with Lewy
671 bodies: Fourth consensus report of the DLB Consortium. *Neurology* *89*, 88–100.
- 672 49. Ozaki, Y., Yoshino, Y., Yamazaki, K., Ochi, S., Iga, J. ichi, Nagai, M., Nomoto, M., and Ueno, S. ichi
673 (2020). DRD2 methylation to differentiate dementia with Lewy bodies from Parkinson's disease. *Acta*
674 *Neurol. Scand.* *141*, 177–182.
- 675 50. Piggott, M.A., Ballard, C.G., Rowan, E., Holmes, C., McKeith, I.G., Jaros, E., Perry, R.H., and Perry,
676 E.K. (2007). Selective loss of dopamine D2 receptors in temporal cortex in dementia with Lewy
677 bodies, association with cognitive decline. *Synapse* *61*, 903–911.


- 678 51. Foo, J.N., Chew, E.G.Y., Chung, S.J., Peng, R., Blauwendraat, C., Nalls, M.A., Mok, K.Y., Satake, W.,
679 Toda, T., Chao, Y., et al. (2020). Identification of Risk Loci for Parkinson Disease in Asians and
680 Comparison of Risk Between Asians and Europeans: A Genome-Wide Association Study. *JAMA*
681 *Neurol.* *77*, 746–754.
- 682 52. Brown, B.C., Asian Genetic Epidemiology Network Type 2 Diabetes Consortium, Ye, C.J., Price,
683 A.L., and Zaitlen, N. (2016). Transethnic Genetic-Correlation Estimates from Summary Statistics. *Am.*
684 *J. Hum. Genet.* *99*, 76–88.
- 685 53. Zerbino, D.R., Achuthan, P., Akanni, W., Amode, M.R., Barrell, D., Bhai, J., Billis, K., Cummins, C.,
686 Gall, A., Girón, C.G., et al. (2018). Ensembl 2018. *Nucleic Acids Res.* *46*, D754–D761.
- 687 54. Chia, R., Sabir, M.S., Bandres-Ciga, S., Saez-Atienzar, S., Reynolds, R.H., Gustavsson, E., Walton,
688 R.L., Ahmed, S., Viollet, C., Ding, J., et al. (2020). Genome sequencing analysis identifies new loci
689 associated with Lewy body dementia and provides insights into the complex genetic architecture.
690 *BioRxiv* 2020.07.06.185066.
- 691 55. Pagès, H. (2017). *SNPlocs.Hsapiens.dbSNP144.GRCh37: SNP locations for Homo sapiens (dbSNP*
692 *Build 144)*. R Packag. Version 0.99.20.
- 693 56. Bulik-Sullivan, B., Loh, P.R., Finucane, H.K., Ripke, S., Yang, J., Patterson, N., Daly, M.J., Price, A.L.,
694 Neale, B.M., Corvin, A., et al. (2015). LD score regression distinguishes confounding from polygenicity
695 in genome-wide association studies. *Nat. Genet.* *47*, 291–295.
- 696 57. Bulik-Sullivan, B., Finucane, H.K., Anttila, V., Gusev, A., Day, F.R., Loh, P.-R., Duncan, L., Perry,
697 J.R.B., Patterson, N., Robinson, E.B., et al. (2015). An atlas of genetic correlations across human
698 diseases and traits. *Nat. Genet.* *47*, 1236–1241.
- 699 58. International HapMap 3 Consortium, Altshuler, D.M., Gibbs, R.A., Peltonen, L., Altshuler, D.M.,
700 Gibbs, R.A., Peltonen, L., Dermitzakis, E., Schaffner, S.F., Yu, F., et al. (2010). Integrating common and
701 rare genetic variation in diverse human populations. *Nature* *467*, 52–58.

- 702 59. 1000 Genomes Project Consortium, Auton, A., Brooks, L.D., Durbin, R.M., Garrison, E.P., Kang,
703 H.M., Korbel, J.O., Marchini, J.L., McCarthy, S., McVean, G.A., et al. (2015). A global reference for
704 human genetic variation. *Nature* 526, 68–74.
- 705 60. R Core Team (2021). R: A language and environment for statistical computing.
- 706 61. Morgan, M. (2021). BiocManager: Access the Bioconductor Project Package Repository.
- 707 62. Gu, Z., Gu, L., Eils, R., Schlesner, M., and Brors, B. (2014). circlize Implements and enhances
708 circular visualization in R. *Bioinformatics* 30, 2811–2812.
- 709 63. Wickham, H. (2016). *ggplot2: Elegant Graphics for Data Analysis* (Springer-Verlag New York).
- 710 64. Pedersen, T.L. (2021). ggraph: An Implementation of Grammar of Graphics for Graphs and
711 Networks.
- 712 65. Wilke, C.O. (2020). cowplot: Streamlined Plot Theme and Plot Annotations for “ggplot2.”
- 713 66. Dowle, M., and Srinivasan, A. (2021). data.table: Extension of `data.frame`.
- 714 67. Corporation, M., and Weston, S. (2020). doSNOW: Foreach Parallel Adaptor for the “snow”
715 Package.
- 716 68. Microsoft, and Weston, S. (2020). foreach: Provides Foreach Looping Construct.
- 717 69. Lawrence, M., Huber, W., Pagès, H., Aboyoun, P., Carlson, M., Gentleman, R., Morgan, M.T., and
718 Carey, V.J. (2013). Software for Computing and Annotating Genomic Ranges. *PLoS Comput. Biol.* 9,
719 e1003118.
- 720 70. Clarke, E., and Sherrill-Mix, S. (2017). ggbeeswarm: Categorical Scatter (Violin Point) Plots.
- 721 71. Kassambara, A. (2020). ggpubr: “ggplot2” Based Publication Ready Plots.
- 722 72. Warnes, G.R., Bolker, B., and Lumley, T. (2021). gtools: Various R Programming Tools.
- 723 73. Müller, K. (2020). here: A Simpler Way to Find Your Files.
- 724 74. Firke, S. (2021). janitor: Simple Tools for Examining and Cleaning Dirty Data.

- 725 75. Bulik-Sullivan, B., Finucane, H.K., Anttila, V., Gusev, A., Day, F.R., Loh, P.-R.R., Duncan, L., Perry,
726 J.R.B.B., Patterson, N., Robinson, E.B., et al. (2015). An atlas of genetic correlations across human
727 diseases and traits. *Nat. Genet.* 47, 1236–1241.
- 728 76. Schaubberger, P., and Walker, A. (2021). *openxlsx: Read, Write and Edit xlsx Files*.
- 729 77. Rinker, T.W. (2015). *{qdapTools}: Tools to Accompany the qdap Package*.
- 730 78. Wickham, H., and Bryan, J. (2019). *readxl: Read Excel Files*.
- 731 79. Lawrence, M., Gentleman, R., and Carey, V. (2009). *rtacklayer: An R package for interfacing with*
732 *genome browsers*. *Bioinformatics* 25, 1841–1842.
- 733 80. Wickham, H., Averick, M., Bryan, J., Chang, W., McGowan, L., François, R., Grolemund, G., Hayes,
734 A., Henry, L., Hester, J., et al. (2019). Welcome to the Tidyverse. *J. Open Source Softw.* 4, 1686.
- 735

736 **Figures**

737




738

739 **Figure 1 Overview of local and global genetic correlations between neurodegenerative diseases and**
 740 **neuropsychiatric disorders.**

741 **(a)** Chord diagram showing the number of significant bivariate local correlations ($p < 0.05/1603$) between each of the
 742 disease traits across all LD blocks. Positive and negative correlations are coloured red and blue, respectively.
 743 **(b)** Comparison between the global correlations estimated by LDSC (bottom) and the mean local correlation from LAVA (top)
 744 across all tested LD blocks. Significant global correlations ($p < 0.05/15$) are indicated with *. The number of significant
 745 local correlations is indicated by a number in each tile. **(c)** Bar plot showing the number of significant local correlations between
 746 disease trait pairs. The fill of the bars indicates the number of significant LD blocks for which the upper limit of
 747 the r^2 95% confidence interval (CI) included 1.


748



749

750 **Figure 2 Local analyses associate disease-implicated genomic regions with previously unrelated traits.**


751 **(a)** Bar plot (left) showing the number of traits within trait pairs demonstrating significant local ρ that had
752 genome-wide significant SNPs overlapping the tested LD block (as illustrated by the schematic on the right). **(b)**
753 Two LD blocks illustrating the situations depicted in **(a)**. Edge diagrams for each LD block show the
754 standardised coefficient for ρ for each significant bivariate local ρ . Significant negative and positive
755 ρ are indicated by blue and red colour, respectively. **(c)** Heatmaps show the ρ for each bivariate local
756 ρ within the LD block. Asterisks (*) indicate ρ that were replicated when using AD and PD GWASs that excluded
757 UK Biobank by-proxy cases. Significant negative and positive ρ are indicated by blue and red fill, respectively.
758 Non-significant ρ have a grey fill. In both **(b)** and **(c)** panels are labelled by the LD block identifier, the traits
759 with genome-wide significant SNPs overlapping the LD block (indicated in the brackets) and the genomic
760 coordinates of the LD block (in the format chromosome:start-end).



761

762 **Figure 3 Multiple regression across LD blocks with multiple trait pair correlations.**

763 For both plots, only those multiple regression models with at least one significant predictor ($p < 0.05$) are
 764 shown. **(a)** Plots of standardised coefficients for each predictor in multiple regression models across each LD
 765 block, with whiskers spanning the 95% confidence interval for the coefficients. Panels are labelled by the LD
 766 block identifier and the regression model. **(b)** Multivariate r^2 for each LD block and model, where multivariate
 767 r^2 represents the proportion of variance in genetic signal for the outcome trait explained by all predictor traits
 768 simultaneously. Whiskers span the 95% confidence interval for the r^2 . ***, $p < 0.001$; **, $p < 0.01$; *, $p < 0.05$.



770 **Figure 4 Incorporation of gene expression traits to facilitate functional interpretation of disease trait**
771 **correlations.**


772 **(a)** Bar plot of the number of eQTL genes (as defined by their genic regions) tested in each LD block. The fill of
773 the bars indicates whether eQTL genes were significantly correlated with at least one disease trait. **(b)** Bar plot
774 of the number of eQTL genes that were significantly correlated with at least one disease trait. The fill of the
775 bars indicates whether eQTL genes in local r_g s were correlated with one or more disease traits. **(c, d, f)**
776 Heatmaps of the standardised coefficient for r_g (ρ) for each significant gene expression-disease trait
777 correlation (FDR < 0.05) within LD block **(c)** 1719, **(d)** 1273 and **(f)** 2351. Genes are ordered left to right on the
778 x-axis by the genomic coordinate of their gene start. Panels are labelled by the eQTL dataset from which eQTL
779 genes were derived (either PsychENCODE's analysis of adult brain tissue from 1387 individuals or the eQTLGen
780 meta-analysis of 31,684 blood samples from 37 cohorts). **(e)** Edge diagrams for representative genic regions
781 show the ρ for each significant bivariate local r_g (FDR < 0.05). GWAS and eQTL nodes are indicated by grey
782 and white fill, respectively. Panels are labelled by the gene tested and the eQTL dataset from which eQTL
783 genes were derived. In panels **c-f** significant negative and positive r_g s are indicated by blue and red colour,
784 respectively.

Tables


Table 1 Overview of traits included in this study. Global SNP heritability (h^2) for each trait was obtained using LDSC⁷⁵. SE, standard error.

Trait type	Trait	Abbreviation	N	N cases	N controls	Global h^2 (SE)	Original study
Disease	Alzheimer's disease Clinically diagnosed + UK Biobank proxy cases and controls	AD	455,258	71,880 (46,613 proxy)	383,378 (318,246 proxy)	1.5% (0.2)	Jansen <i>et al.</i> , 2019 ¹⁹
Disease	Alzheimer's disease Clinically diagnosed	AD (no proxy)	63,926	21,982	41,944	7.1% (1.1)	Kunkle <i>et al.</i> , 2019 ²⁰
Disease	Bipolar disorder	BIP	413,466	41,917	371,549	7.1% (0.3)	Mullins <i>et al.</i> , 2021 ²²
Disease	Lewy body dementia Autopsy-confirmed + clinically diagnosed	LBD	6,618	2,591 (1,789 autopsy-confirmed)	4,027	17.1% (7.6)	Chia <i>et al.</i> , 2021 ⁵
Disease	Major depressive disorder	MDD	500,199	170,756	329,443	6% (0.2)	Howard <i>et al.</i> , 2019 ²¹
Disease	Parkinson's disease excluding 23andMe Clinically diagnosed + UK Biobank proxy cases and controls	PD	482,730	33,674 (18,618 proxy)	449,056 (436,419 proxy)	1.9% (0.2)	Nalls <i>et al.</i> , 2019 ³
Disease	Parkinson's disease excluding 23andMe Clinically diagnosed	PD (no proxy)	27,693	15,056	12,637	30.6% (2.8)	Nalls <i>et al.</i> , 2019 ³
Disease	Schizophrenia	SCZ	105,318	40,675	64,643	41% (1.4)	Pardiñas <i>et al.</i> , 2018 ²³
Gene expression	eQTLGen Blood-derived eQTLs	eQTLGEN	31,684	-	-	-	Vosā <i>et al.</i> , 2021 ³³
Gene expression	PsychENCODE Brain-derived eQTLs	PSYCHENCODE	1,387	-	-	-	Wang <i>et al.</i> , 2018 ³⁴

Supplementary Figures



Supplementary Figure 1 (a) Number of LD blocks containing genome-wide significant loci per chromosome. Chromosomes have been ordered by the total number of LD blocks in each chromosome. (b) Number of genome-wide significant AD, BIP, LBD, MDD, PD and SCZ SNPs per autosome.




Supplementary Figure 2 Impact of excluding UK Biobank by-proxy cases on local genetic correlations and multiple regression.

(a) Scatter plot of $-\log_{10}(p\text{-value})$ and the standardised coefficient for (ρ, ρ) for each pair of phenotypes with sufficient univariate signal to carry out a bivariate test using AD/PD GWASs with or without by-proxy cases. In each panel, Pearson's coefficient (R) and associated p -value (p) are displayed. The black dashed line represents the line $y = x$. Points are coloured, where applicable, by whether they share the same direction of effect. **(b)** Significant bivariate local genetic correlations using AD/PD GWASs with or without by-proxy cases (as indicated in panel headers). Heatmaps show the ρ for all tested associations within the LD block, with significant negative and positive correlations indicated by blue and red fill, respectively. Non-significant correlations have a grey fill. **(c)** Results of multiple regression model across LD block 2351. Plot (left) of standardised coefficients for each predictor in multiple regression model in LD block 2351, with whiskers spanning the 95% confidence interval for the coefficients. Plot (right) of multivariate r^2 for LD block 2351, where multivariate r^2 represents the proportion of variance in genetic signal for LBD explained by AD and PD simultaneously. Whiskers span the 95% confidence interval for the multivariate r^2 . ***, $p < 0.001$.


Supplementary Figure 3 Local gene expression and disease trait correlations across 5 LD blocks of interest.

Heatmaps of the standardised coefficient for r_g (ρ) for all tested gene expression-disease trait correlation within LD block **(a)** 681, **(b)** 1273, **(c)** 1719, **(d)** 2281 and **(e)** 2351. All negative and positive r_g s with $p < 0.05$ are indicated by blue and red colour, respectively, while the remainder have a grey fill. Significant local r_g s (FDR < 0.05) are indicated by two asterisks (**), while nominally significant local r_g s ($p < 0.05$) are indicated with a black square (■). Genes are ordered left to right on the x-axis by the genomic coordinate of their gene start.



Supplementary Figure 4 Explained variance in trait pairs with different trait types.

Boxplot of explained variance (r^2 , the proportion of variance in genetic signal of one disease trait in a pair explained by the other) in trait pairs involving a disease and gene expression trait (gwas-eqtl) or two disease traits (gwas-gwas). Only local r_g s that passed significance are plotted (FDR < 0.05; N, local r_g s = 87).



Supplementary Figure 5 Effect of window size on local genetic correlations.

(a) Number of significant bivariate local r_g 's across window sizes. Bars are coloured by whether r_g 's are significant across both window sizes (shared) or only one (unique). (b) Scatter plot of $-\log_{10}(p\text{-value})$ and the standardised coefficient for (ρ, p) for each pair of phenotypes that could be tested across genic regions with a 50-kb or 100-kb window. Panels indicate whether the pair of phenotypes included a disease and gene expression trait (gwas-eqtl) or two disease traits (gwas-gwas). Points are coloured by whether they share the same direction of effect. The black line represents a linear model fitted to the data, with the 99% confidence interval indicated with a grey fill. Further, Pearson's coefficient (R) and associated p -value (p) are displayed. The red dashed line represents the line $y = x$.

Supplementary Tables

Supplementary Table 1 LD blocks, their associated disease traits (as determined by overlap of genome-wide significant SNPs) and overlapping genes.

Supplementary Table 2 Results of LDSC using the six disease traits.

Supplementary Table 3 Results of LAVA using the six disease traits.

Supplementary Table 4 Results of LAVA using GWASs for AD and PD that exclude UK Biobank by-proxy cases.

Supplementary Table 5 Results of multiple regression analyses.

Supplementary Table 6 Results of LAVA using disease and gene expression traits (100-kb window). Sheets containing bivariate results for each LD block also contain (a) locus plot of genic regions (including 100-kb window). Significant bivariate local genetic correlations between a disease and gene expression trait are highlighted in blue (FDR < 0.05). (b) Edge diagrams for genic regions where a significant bivariate local genetic correlation was observed between a disease and gene expression trait (FDR < 0.05). Edges display the standardised coefficient for genetic correlation (ρ) for significant bivariate local genetic correlations, with negative and positive correlations indicated by blue and red colour, respectively. GWAS and eQTL nodes are indicated by grey and white fill, respectively.

Supplementary Table 7 Results of LAVA using disease and gene expression traits (50-kb window). Sheets containing bivariate results for each LD block also contain (a) locus plot of genic regions (including 50-kb window). Significant bivariate local genetic correlations between a disease and gene expression trait are highlighted in blue (FDR < 0.05). (b) Edge diagrams for genic regions where a significant bivariate local genetic correlation was observed between a disease and gene expression trait (FDR < 0.05). Edges display the standardised coefficient for genetic correlation (ρ) for significant bivariate local genetic correlations, with negative and positive correlations indicated by blue and red colour, respectively. GWAS and eQTL nodes are indicated by grey and white fill, respectively.